Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study
Ñamendys-Silva et al.
, Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study
, Heart & Lung, doi:10.1016/j.hrtlng.2020.10.013
Retrospective 164 ICU patients in Mexico showing 32% lower mortality with HCQ+AZ and 37% lower with CQ.
HCQ+AZ vs. neither HCQ or CQ relative risk RR 0.68, p
CQ vs. neither HCQ or CQ relative risk RR 0.63, p
HCQ+AZ or CQ vs. neither relative risk RR 0.65, p
risk of death, 32.3% lower, RR 0.68, p = 0.18, treatment 24 of 54 (44.4%), control 42 of 64 (65.6%), NNT 4.7, HCQ+AZ vs. neither HCQ or CQ.
risk of death, 37.1% lower, RR 0.63, p = 0.09, treatment 19 of 46 (41.3%), control 42 of 64 (65.6%), NNT 4.1, CQ vs. neither HCQ or CQ.
risk of death, 34.5% lower, RR 0.66, p = 0.006, treatment 43 of 100 (43.0%), control 42 of 64 (65.6%), NNT 4.4, HCQ+AZ or CQ.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ñamendys-Silva et al., 21 Oct 2020, retrospective, database analysis, Mexico, peer-reviewed, mean age 57.3, 18 authors, average treatment delay 7.0 days.
Abstract: Heart & Lung 50 (2021) 28 32
Contents lists available at ScienceDirect
Heart & Lung
journal homepage: www.heartandlung.com
Outcomes of patients with COVID-19 in the intensive care unit in Mexico:
A multicenter observational study
Silvio A. Namendys-Silva,
MD, MSc, FCCP, FCCMa,h,*, Pedro E. Alvarado-Avila,
Guillermo Domínguez-Cherit, MD, FCCM , Eduardo Rivero-Sigarroa, MD ,
nchez-Hurtado, MDc, Alan Gutie
~ or, MDd,
Luis A. Sa
lez, MDd, Heber Rodríguez-Bautista, MDa, Alondra García-Briones, MDd,
Juan P. Romero-Gonza
stor G. Cruz-Ruiz, MDf, María O. Gonza
sar E. Garnica-Camacho, MDe, Ne
rrez, MD ,
n, MD , Manuel A. Guerrero-Gutie
Francisco J. García-Guille
L. Canto-Castro, MDj,
Jose D. Salmeron-Gonzalez, MD , Laura Romero-Gutierrez, MDc, Jose
Victor H. Cervantes, MDk, on behalf of the Mexico COVID-19 Critical Care Collaborative Group
n, Mexico City 14000, Mexico
n Salvador Zubira
Instituto Nacional de Ciencias Medicas y Nutricio
gico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico
Hospital de Especialidades del Centro Medico Nacional Siglo XXI, IMSS, Mexico City, Mexico
Hospital Medica Sur, Mexico City, Mexico
Hospital General de Zona No.1 “Dr. Enrique Von Borstel Labastida”, IMSS, La Paz, Baja California Sur, Mexico
Hospital General de Zona No. 1, “Dr. Demetrio Mayoral Pardo”, IMSS, Oaxaca, Mexico
Hospital General de Zona 1, IMSS, Tlaxcala, Mexico
Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Hospital General “Dr. Miguel Silva”, Morelia, Michoaca
Unidad Medica de Alta Especialidad "Ignacio García Tellez", IMSS, Merida, Yucata
n, Guanajuato, Mexico
Hospital General Regional No. 58, IMSS, Leo
A R T I C L E
I N F O
Received 23 July 2020
Revised 16 October 2020
Accepted 20 October 2020
Available online 21 October 2020
Intensive care unit
A B S T R A C T
Background: As of June 15, 2020, a cumulative total of 7,823,289 conﬁrmed cases of COVID-19 have been
reported across 216 countries and territories worldwide. However, there is little information on the clinical
characteristics and outcomes of critically ill patients with severe COVID-19 who were admitted to intensive
care units (ICUs) in Latin America. The present study evaluated the clinical characteristics and outcomes of
critically ill patients with severe COVID-19 who were admitted to ICUs in Mexico.
Methods: This was a multicenter observational study that included 164 critically ill patients with laboratoryconﬁrmed COVID-19 who were admitted to 10 ICUs in Mexico, from April 1 to April 30, 2020. Demographic
data, comorbid conditions, clinical presentation, treatment, and outcomes were collected and analyzed. The
date of ﬁnal follow-up was June 4, 2020.
Results: A total of 164 patients with severe COVID-19 were included in this study. The mean age of patients
was 57.3 years (SD 13.7), 114 (69.5%) were men, and 6.0% were healthcare workers. Comorbid conditions
were common in patients with critical COVID-19: 38.4% of patients had hypertension and 32.3% had diabetes.
Compared to survivors, nonsurvivors were older and more likely to have diabetes, hypertension or other conditions. Patients presented to the hospital a median of 7 days (IQR 4.5 9) after symptom onset. The most
common presenting symptoms were shortness of..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.